The NIHR have recently published an article on the STAMPEDE trial which is helping to improve the prognosis and quality of life of those diagnosed with prostate cancer.
This is a research study that’s supported by the NIHR, and has been up and running since 2005, with more than 10,000 men having taken part. 125 UK sites are conducting the research, with local NHS Trusts amongst those 125.
The trial is multi-arm, so compares different treatments amongst the participant group – it is also ‘randomised’, so participants are allocated their treatment at random, reducing any bias in allocation.
The results to date from the trial have also influenced the NHS treatment for men with high risk, locally advanced metastatic prostate cancer. More STAMPEDE related news can be found on their website.
You can read the article here, which contains a testimony from a trial participant whose condition and quality of life have been vastly improved.
Prostate Cancer Research Centre – your chance to influence their next call
New report highlights how NIHR support for clinical research benefits the UK economy and NHS
Cancer and Nutrition NIHR Infrastructure Collaboration
RKEDF – Overview of NIHR, CRNs and NIHR portfolio
Upcoming opportunities for PGRs – collaborate externally
BU involved in new MRF dissemination grant
New COVID-19 publication
MSCA Postdoctoral Fellowships 2024
Horizon Europe News – December 2023